Evidence for a causal link between lipoprotein (a) and mental disorders: A retrospective and Mendelian randomization study
Guanrui Pan,
No information about this author
Qingan Fu,
No information about this author
Yuan Xu
No information about this author
et al.
Journal of Affective Disorders,
Journal Year:
2025,
Volume and Issue:
374, P. 397 - 407
Published: Jan. 12, 2025
Language: Английский
ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease
European Heart Journal,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 28, 2025
Abstract
Background
and
Aims
Apolipoprotein
B
concentration
reflects
the
number
of
atherogenic
lipoproteins
is
recognized
as
a
key
lipid
risk
marker.
Whether
type
or
size
apoB
particle
(apoB-P)
adds
predictive
value
for
coronary
artery
disease
(CAD)
remains
unclear.
Methods
A
prospective
analysis
207
368
UK
Biobank
participants
with
comprehensive
lipoprotein
profiling
no
prior
history
atherosclerotic
disease,
diabetes,
active
lipid-lowering
therapy
was
conducted.
Multivariable-adjusted
Cox
regression
models
were
used
to
examine
association
between
each
following
parameters
incident
CAD:
(i)
nuclear
magnetic
resonance-measured
apoB-P,
(ii)
concentrations
individual
classes
[very-low-density
(VLDL),
low-density
(LDL)],
(iii)
subclasses,
(iv)
average
diameter,
(v)
immunoassay-measured
lipoprotein(a)
[Lp(a)].
Results
one
standard
deviation
(SD)
increase
in
apoB-P
associated
33%
higher
CAD
[hazard
ratio
(HR):
1.33,
95%
CI:
1.30–1.36].
Although
VLDL
particles
observed
carry
per-particle
(HR
per
100
nmol/L:
1.22,
1.11–1.34)
compared
LDL
1.07,
1.05–1.08),
this
difference
counterbalanced
after
considering
relative
abundance
(LDL
91%
vs
9%
total
apoB-P).
Thus
respective
HR
1-SD
1.09
(1.05–1.14)
1.24
(1.19–1.30).
Particle
diameter
subclasses
not
adjustment.
The
Lp(a)
robust
even
adjustment
(HR:1.18,
1.16–1.20)
added
independent
prognostic
(area
under
curve:
0.769
0.774,
P
<
.001).
Conclusions
Lipid-related
most
accurately
reflected
by
count
largely
unaffected
major
(VLDL,
LDL)
size.
Elevated
additional
risk,
thus
adequate
assessment
from
dyslipidemia
best
accomplished
consideration
both
concentrations.
Language: Английский
Lipoprotein(a) and the atherosclerotic burden – should we wait for clinical trial evidence before taking action?
Atherosclerosis Plus,
Journal Year:
2024,
Volume and Issue:
58, P. 16 - 23
Published: Sept. 26, 2024
Language: Английский
In Search of an Accurate Measurement of LDL-C
Sotirios Tsimikas,
No information about this author
Calvin Yeang,
No information about this author
Florian Kronenberg
No information about this author
et al.
Journal of the American College of Cardiology,
Journal Year:
2024,
Volume and Issue:
84(2), P. 178 - 181
Published: July 1, 2024
Language: Английский
Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk
Lipids in Health and Disease,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Sept. 27, 2024
Language: Английский
Coronary Plaque Characteristics Assessed by Optical Coherence Tomography and Plasma Lipoprotein(a) Levels in Patients With Acute Coronary Syndrome
Catheterization and Cardiovascular Interventions,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 27, 2024
Lipoprotein(a)
[Lp(a)]
is
associated
with
increased
cardiovascular
risk,
but
its
influence
on
plaque
characteristics
at
optical
coherence
tomography
(OCT)
evaluation
not
fully
understood.
Language: Английский